Skip to content
Search AI Powered

Latest Stories

Big News From NY's Office Of Cannabis Management (OCM) On Regulations

New York's OCM Delivers Big Improvements on Cannabis Regulations
New York's OCM Delivers Big Improvements on Cannabis Regulations

In an exciting development for New York’s burgeoning yet hobbled cannabis industry, the Office of Cannabis Management (OCM) has released a set of revised regulations that will shape the future of cannabis businesses in the state. 

These new regulations bring about significant, yet much needed changes to licensing, co-location, compensation arrangements, purchasing limits, and consumption areas, offering both opportunities and clarity for NY’s cannabis entrepreneurs and consumers alike.


One of the key highlights of the revised regulations is the introduction of the provisional license. Under this new framework, applicants without a pre-determined location can now obtain a provisional license by submitting initial information about their business and demonstrating their eligibility. This approach aims to reduce upfront costs and overhead for applicants and provide them with a "pre-approval" from the State while they search for a suitable location, secure funding, and assemble their teams. Additionally, the regulations outline with more clarity the general application process, enabling prospective applicants to prepare the necessary materials in advance of formal application windows.

Another significant update is the allowance for co-located adult-use and medical dispensaries. Starting from December 29, 2023, the first co-located store from an existing RO’s (Registered Organization) can open its doors, followed by the second and third co-located dispensaries after June 29, 2024. To facilitate this transition and maintain a fair and equitable marketplace, a fee structure has also been established. Co-location licensure for RO’s requires an initial payment of $5 million, with the remaining amount due upon the opening of the second co-located dispensary or in $5 million installments, to be paid within 30 days of each $100 million in revenue generated by the dispensary, up to a maximum of $300 million. 

To encourage the participation of True Parties of Interest (TPI) in New York’s adult-use cannabis industry, the annual compensation arrangement threshold has been increased. TPIs, individuals who have a significant financial interest in a cannabis license or application, will now need to meet the highest of three criteria: 10% of gross revenue, 50% of net revenues, or $250,000. This adjustment aims to provide fair compensation to those contributing to the success of cannabis businesses.

Microbusiness license holders have also received favorable updates. They can now purchase up to 500 pounds of cannabis biomass per year, ensuring a reliable supply for their operations. In exceptional circumstances such as crop failure, they may also have the flexibility to acquire additional biomass, safeguarding their businesses against potentially catastrophic disruptions.

Furthermore, the revised regulations create multiple avenues for licensed adult-use cannabis businesses and local governments to establish designated areas for cannabis consumption. In addition to on-site consumption licenses, retail dispensaries can now designate a distinct area on their premises called a Limited Retail Consumption Facility. Accessible only to individuals aged 21 and above, this area allows customers to use the cannabis products they have purchased in a controlled environment. The revised draft regulations also grant local governments the power to identify cannabis consumption areas within their jurisdictions, exempting certain spaces from the Clean Indoor Air Act.

While the changes have been largely seen as positive, it is important to acknowledge the diverse perspectives surrounding these new regulations.

While the revised regulations announced yesterday by the Office of Cannabis Management (OCM) have been largerely seen as positive, they have generated significant discussion and debate within the New York cannabis industry and within the broader cannabis industry. It is therefore extremely important to acknowledge the diverse perspectives surroounding these new regulations.  

For instance, re: Provisional Licensing: While the introduction of provisional licenses has been hailed as a way to reduce upfront costs for applicants, there are concerns about the potential drawbacks. Critics argue that this approach may lead to an oversaturation of provisional license holders who are still searching for suitable locations. This could potentially result in increased competition and market volatility, making it more challenging for businesses to thrive in an already competitive landscape.

With regards to Co-located Dispensaries (Medical + Adult Use), some view the fee structure associated with this transition as prohibitively expensive. These critics argue that the $5 million initial payment and subsequent installments based on revenue may present significant financial barriers for businesses seeking to establish co-located dispensaries. This aspect of the regulations could limit the ability of small businesses to participate in this aspect of the market.

The increase in the annual compensation arrangement threshold for True Parties of Interest (TPI) has generated mixed reactions. While proponents argue that this adjustment ensures fair consideration for TPIs, others contend that it may exclude smaller stakeholders from participating in the industry. The new threshold could disproportionately favor larger investors and businesses, potentially stifling diversity and inclusion within the cannabis market.

The allowance for microbusiness licensees to purchase up to 500 pounds of cannabis biomass per year has generally been seen as a positive development. However, there are some concerns about the definition of "business-threatening circumstances" that would permit additional biomass purchases. Critics argue that vague criteria may lead to inconsistent enforcement and potential misuse, potentially disadvantageous to smaller businesses that genuinely face critical challenges.

The creation of pathways for designated cannabis consumption areas has sparked discussions about the implications for public health and safety. While the regulations aim to provide controlled environments for cannabis consumption, opponents worry about the potential negative effects on communities and the overall normalization of cannabis use. Striking a balance between consumer freedoms and responsible regulation remains a challenge in this aspect of the industry.

According to cannabis attorney Jeffrey Hoffman of Jeffrey Hoffman & Associates, "These new regulations are smart and a game changer and have the capacity to bring about substantial transformations and advancements within the industry.

Asked about the regs around on-site consumption, Mr. Hoffman believes “it is what will differentiate NY, and especially NYC." 

As Mr. Hoffman noted, the differentiation that these regulations seemingly deliver specifically for New York, and more prominently for New York City, underscores the belief that these regulations will set the state and its largest city apart from other regions, potentially paving the way for unique opportunities and market dynamics.

These revised regulations not only provide a framework for the future of cannabis businesses in New York but also prioritize consumer safety, economic growth, and entrepreneurial opportunities. With the revised regulations now in effect, aspiring cannabis entrepreneurs and enthusiasts can confidently embark on their journeys in this rapidly evolving industry.

The diverse perspectives within the industry continue to contribute to a broader and necessary dialogue that aims to shape a thriving and inclusive cannabis market in New York.

More For You

map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report byThe New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy

Selective Outrage Hurts NY Cannabis

Authored by: Veterans Holdings CEO Jason Ambrosino

Last week, the New York Medical Cannabis Industry Association (NYMCIA) issued a press release accusing licensed dispensaries of selling "out-of-state cannabis" and undermining the integrity of the legal market. Read the press release here.

Keep ReadingShow less
image of a circle of doctors and surgeons standing over and looking at a patient on operating room table
New Study Confirms Medical Cannabis Benefits in Cancer Care—Time for Policy to Catch Up
Photo by National Cancer Institute on Unsplash

Cannabis & Cancer: The Evidence Is In—So Why Is the Medical Establishment Still Dragging Its Feet?

If you've ever watched a loved one battle cancer—or been on that journey yourself—you already know the harsh truth: the pain is real, the nausea is relentless, the appetite is gone, and the side effects of treatment often feel worse than the disease. So when patients say cannabis helps, it shouldn’t take 10,000 studies for the medical community to take them seriously.

And yet, here we are.

Keep ReadingShow less
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Giphy

Aging & Cannabis: New Findings

For decades, cannabis has been widely regarded as a substance with potential cognitive risks, particularly when used over long periods. Governments across the globe have classified it as a controlled substance, citing concerns about the effects of marijuana use, including memory loss, diminished executive function, and long-term neurological impact. But new research is challenging this long-standing assumption, suggesting that cannabis use may not be linked to age-related cognitive decline—and might even be associated with better cognitive preservation over time.

A recent study published in PubMed (NIH, 2024) followed over 5,000 men for more than four decades to analyze the long-term cognitive effects of cannabis use. The results? Men with a history of cannabis use experienced less cognitive decline from early adulthood to late midlife compared to those who never used cannabis.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less